热门资讯> 正文

FDA扩大Ascendis侏儒症候选药物审查

2025-11-28 23:22

Ascendis制药(ASND) 0
富国银行(WFC) 0

The US FDA has extended the review time of an NDA for Ascendis Pharma's (ASND) TransCon CNP (navepegritide), a treatment for children with achondroplasia.
The action date is extended by three months to Feb. 28, 2026.
The reason for the extension is additional information submitted by the company on Nov. 5 connected to a post-marketing requirement was deemed a major amendment to the application.

More on Ascendis Pharma

Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Ascendis Pharma GAAP EPS of - €1.00, revenue of €213.63M
Ascendis Pharma Q3 2025 Earnings Preview
Seeking Alpha’s Quant Rating on Ascendis Pharma

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。